You are here:Home>Prostate Cancer/ Movember campaign
Prostate Cancer Awareness Month brings attention to the men living with this disease. Pharma Intelligence’s Report Store is offering 20% off select prostate cancer reports covering key marketed and pipeline drugs, clinical trials, and more.
Use code: prostate20 at checkout to instantly get 20% discount.
This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends & opportunities in the nearly $1bn Prostate Cancer Diagnostics and Minimally Invasive Treatments market.
Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size.
The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.